Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3017 in relapsed or refractory CD30-positive classical Hodgkin lymphoma and non-Hodgkin lymphoma
jRCT2031230576Phase 1Completed
- Sponsor
- Genmab
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of gen3017 in classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma (NHL) and T-cell lymphoma (2 arms), sponsored by Genmab. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and 1 more. Started Oct 2024; status: completed.
02
Drugs
gen3017
03
Conditions
classical Hodgkin lymphoma (cHL)non-Hodgkin lymphoma (NHL)T-cell lymphoma
Beyond the preview
Go deeper on jRCT2031230576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230576.